CD274 and non-small cell lung carcinoma: Nivolumab was approved by the FDA to treat patients with metastatic squamous NSCLC in 2015.[9] Prembrolizumab was approved by FDA as first-line treatment in metastatic NSCLC with high PD-L1 expression in 2016.[12] The combination of pembrolizumab and chemotherapy to treat NSCLC was approved by the FDA in May 2017.